Aaron Green, the Chief Executive Officer of OneMedNet Corp (NASDAQ: ONMD), has completed a direct acquisition of company shares on June 23, 2026. The transaction involved the purchase of 36,650 shares of OneMedNet common stock in the open market. Each share was acquired at a price of $0.5733, resulting in a total transaction value of $21,011.
Following this acquisition, Mr. Green's direct ownership of OneMedNet Corp common stock has increased to 1,896,375 shares. The insider purchase occurs as the company's stock trades at approximately $0.60, a level near its 52-week low of $0.44. This valuation reflects a broader trend of a 55% decline in the stock price over the preceding six months. OneMedNet's current market capitalization is recorded at $32.7 million.
Financial data from InvestingPro analysis indicates that the company is expending cash rapidly while simultaneously achieving a 148% revenue increase over the last twelve months. In recent quarterly reports, OneMedNet Corporation announced a 329% surge in revenue for 2025, reaching $1.25 million, compared to $292,000 in 2024. The company's fourth-quarter revenue specifically totaled $890,000.
Operational adjustments have also contributed to a 74% reduction in liabilities. The firm's debt decreased from $19.7 million at the end of 2024 to $5.1 million by the end of 2025. Additionally, OneMedNet secured more than $3 million in bookings for 2026, exceeding its total bookings for 2025. These bookings are projected to be recognized as revenue by the end of the third quarter of 2026.
Strategic developments include a partnership with Inka Health to provide access to its iRWD platform for oncology data. This collaboration supports the development of Onco-Innovations' cancer treatment technology. Despite these advancements, OneMedNet received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement. The company has until October 12, 2026, to regain compliance.
These activities underscore OneMedNet's ongoing efforts to strengthen its financial position and expand strategic partnerships within the healthcare technology sector. The company's trajectory reflects the complexities of managing growth, cash flow, and regulatory standards in the biotechnology and medical device industries.